Crinetics Shareholders Approve $10B Vertex Merger; Golden Parachute Vote Fails
CRNX has more than doubled off its 52-week low of $30.25 on light trading volume (0.2× avg).
Summary
Crinetics shareholders approved the $10 billion Vertex acquisition at $85 per share, with closing expected around September 1, 2026. The advisory vote on executive merger compensation failed but is non-binding.
Key Events · M&A and Partnerships · CRNX
-
Merger Proposal Approved
Shareholders approved the Vertex merger with 79,240,098 votes for (99.97% of votes cast), 13,618 against, and 10,915 abstained. Quorum was 74.71% of outstanding shares.
-
Golden Parachute Vote Fails
The non-binding advisory vote on executive merger compensation failed: 33,854,149 for vs 44,803,403 against (56.9% against). This does not affect merger completion.
-
Closing Expected September 1, 2026
Shareholder approval satisfies the final outstanding condition. Crinetics anticipates closing on or about September 1, 2026, at $85.00 per share in cash.
-
Deal Context
Vertex agreed to acquire Crinetics for $10 billion on July 6, 2026. HSR and international antitrust approvals were received by August 14, 2026.
Analysis · CRNX · Life Sciences
Crinetics shareholders overwhelmingly approved the $85-per-share all-cash acquisition by Vertex, clearing the final condition to closing. The merger proposal passed with 99.97% of votes cast, and the company now expects to close on or about September 1, 2026. Notably, the non-binding advisory vote on executive golden parachute compensation failed — 56.9% of shareholders voted against it — but this does not block the deal. The stock trades at $84.84, just below the $85.00 deal price, reflecting near-certainty of completion.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRNX was trading at $84.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $30.25 to $84.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.